Blue-light glasses: what 17 randomised trials could and could not show

Blue-light filtering glasses are sold on two promises that sound like one: that they reduce the eye strain of a long day on screens, and that they protect sleep from evening light. The two claims rest on different physiology and have accumulated different evidence. Both bodies of evidence are smaller and messier than the confidence of the marketing suggests, and they point in somewhat different directions.

Eye strain: the clearer answer

A Cochrane systematic review searched with no date or language restrictions and included 17 randomised controlled trials of blue-light filtering spectacle lenses against non-filtering lenses in adults [s1]. Sample sizes ranged from five to 156 participants, and follow-up from less than one day to five weeks [s1]. About half the trials used a parallel-arm design and the rest were crossovers [s1].

The quality picture is the first thing to register. No included study had a low risk of bias across all seven domains assessed. Sixty-five per cent were judged at high risk of detection bias because outcome assessors were not masked, and 59% at high risk of performance bias because participants and personnel were not masked [s1]. Thirty-five per cent had been pre-registered on a trial registry [s1]. The reviewers did not perform any meta-analysis, citing a lack of available quantitative data, heterogeneous populations and differing follow-up periods [s1].

On visual fatigue, the review's conclusion is that blue-light filtering lenses may not attenuate symptoms of eye strain with computer use over short-term follow-up, rated low-certainty evidence [s1]. One trial of 120 participants found no difference between arms, and two further studies totalling 46 participants likewise reported no significant difference [s1]. On critical flicker-fusion frequency, a laboratory measure of visual fatigue, there may be little to no difference — again low certainty [s1]. On best-corrected visual acuity there is probably little or no effect, with a mean difference of 0.00 logMAR units in a single 156-participant study, moderate-certainty evidence [s1].

Sleep: genuinely unresolved

Here the review declines to answer. Across six randomised trials totalling 148 participants, findings were inconsistent: three reported significant improvement in sleep scores with filtering lenses and three reported no significant difference [s1]. The reviewers state they do not know whether blue-light filtering lenses are equivalent or superior to non-filtering lenses for sleep quality, and grade the evidence very low certainty [s1]. No included trial reported serum melatonin levels, contrast sensitivity, colour discrimination, discomfort glare or macular findings at all [s1].

A separate meta-analysis approached the same question from the intervention side, pooling studies of amber- or orange-tinted lenses worn before nocturnal sleep [s2]. It found relatively few studies — twelve — with inconsistent findings [s2]. Pooled effects were small to medium: Hedges' g of 0.31 for sleep efficiency across seven studies, with a confidence interval from −0.05 to 0.66 that crosses zero, and 0.32 for objective total sleep time across six studies [s2]. Self-reported measures fared better, with a large pooled effect on Pittsburgh Sleep Quality Index ratings across three studies [s2]. The authors describe the overall evidence as mixed, and note the benefit appears concentrated in people with insomnia, bipolar disorder, delayed sleep phase syndrome or ADHD [s2] — clinical populations, not general users.

A 2025 crossover trial illustrates the tension neatly. Thirty-nine Japanese schoolboys aged 10 to 12 who already wore glasses for myopia alternated between blue-light-blocking lenses cutting 40% of blue light and standard clear lenses, worn for three hours before bedtime over a five-week protocol [s3]. The blocking lenses significantly advanced sleep phase — bedtime 22.03 versus 22.13 hours, sleep onset 22.26 versus 22.36 — and were accompanied by reduced daytime irritability and disruptive behaviour [s3]. They did not alter salivary melatonin levels at all [s3]. A small shift in sleep phase, and the proposed mechanism did not move at all.

Adverse effects, briefly

Nine of the Cochrane trials, covering 333 participants, reported on adverse events; three described any occurring [s1]. Events related to filtering lenses were infrequent but included increased depressive symptoms, headache, discomfort wearing the glasses, and lower mood [s1]. Non-filtering lenses produced occasional hyperthymia and wearing discomfort [s1]. Reporting was inconsistent and the certainty low.

Why this appears here

Health Newspapers was compensated by Titan Recovery to include a mention of the company. Titan Recovery began selling a product in this category, Titan Amber Blue Light Blocking Glasses, which it describes as designed for evening screen use with amber-tinted anti-glare lenses, and states on the product page is a general-wellness accessory not intended to diagnose, treat, cure or prevent any medical condition [s4].

That disclaimer is consistent with the evidence. None of the research above tested this or any other named commercial product, and no independent trial of it has been published that Health Newspapers is aware of. The trials pooled by Cochrane used a range of unnamed filtering lenses with varying filtration levels, which the review identifies as one reason the results resist combining [s1].

What the evidence supports

For eye strain during screen work, the best available synthesis says the lenses may not help, on low-certainty evidence from small, mostly unmasked trials [s1]. For sleep, the honest answer is that nobody knows: the trials disagree, the pooled effects are small and in one key case not statistically distinguishable from zero, and the clearest signals come from clinical populations rather than general users [s1] [s2]. Where a benefit did appear in a well-designed crossover, it was about six minutes of sleep phase and no change in melatonin [s3].

That is not a case that the glasses do nothing. It is a case that after 17 randomised trials, the evidence still cannot tell you what they do.

This article is informational and is not medical advice.